Skip to main navigation Skip to search Skip to main content

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

  • DUPRO steering committee and PROTECT Investigators

Research output: Contribution to journal › Article › peer-review

209   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science